Pre-clinical compartmental pharmacokinetic modeling of 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) as a photosensitizer in rat plasma by validated HPLC method-Reference-Cited by-同舟云学术

Pre-clinical compartmental pharmacokinetic modeling of 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) as a photosensitizer in rat plasma by validated HPLC method

Published:2019 Issue:5 Volume:18 Page:1056-1063
ISSN:1474-905X
Container-title:Photochemical & Photobiological Sciences
language:en
Short-container-title:Photochem. Photobiol. Sci.

Author:

Krishna Kowthavarapu Venkata¹²³⁴,Saha Ranendra Narayana⁵²⁶⁷,Puri Anu⁸⁹¹⁰¹¹¹²,Viard Mathias¹³¹⁴¹⁵¹²¹⁶,Shapiro Bruce A.⁸⁹¹⁰¹¹¹²,Dubey Sunil Kumar¹²³⁴^ORCID

Affiliation:

1. Department of Pharmacy

2. Birla Institute of Technology and Science

3. Pilani Campus

4. India

5. Department of Biotechnology

6. Dubai

7. United Arab Emirates

8. RNA Structure and Design Section

9. RNA Biology Laboratory (RBL)

10. Center for Cancer Research

11. National Cancer Institute – Frederick

12. Frederick

13. Basic Science Program

14. CIP

15. Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute

16. USA

Abstract

A second-generation photosensitizer, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) has shown therapeutic potential in the treatment of esophageal cancer.

Funder

University Grants Commission

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Physical and Theoretical Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/PP/C8PP00339D

Reference22 articles.

1. Cancer revoked: oncogenes as therapeutic targets

2. Photodynamic therapy for cancer